Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07951060
PHASE1/PHASE2

LP-184 for Advanced or Metastatic Urothelial Carcinoma Selected by PTGR1 Expression and DNA Repair Deficiency

Sponsor: Kristoffer Rohrberg

View on ClinicalTrials.gov

Summary

This study investigates the safety and potential antitumor activity of LP-184 in patients with advanced or metastatic urothelial carcinoma. LP-184 is an investigational anticancer drug designed to damage the DNA of cancer cells. Certain cancer cells may be particularly sensitive to LP-184 if they have impaired DNA repair mechanisms and express a protein called PTGR1, which is involved in activating the drug. The study aims to investigate whether LP-184 can be safely administered and whether it can reduce tumor growth in patients whose tumors have these specific characteristics. The study consists of two parts. Phase Ib will evaluate the safety and tolerability of LP-184 and determine the recommended dose for Phase II. Phase II will investigate the antitumor activity of LP-184 by assessing tumor response to treatment. All participants will receive LP-184 intravenously on days 1 and 8 of each 21-day treatment cycle. Up to 39 patients will be enrolled in the study.

Official title: EXUROC Bladder Target - LP-184, an Acylfulvene, for PTGR1-positive, DNA Repair-deficient Urothelial Carcinoma. A Phase Ib/II Study of Safety, Tolerability, and Efficacy in Advanced/Metastatic Urothelial Carcinoma

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

39

Start Date

2026-11-30

Completion Date

2031-11

Last Updated

2026-11-20

Healthy Volunteers

No

Interventions

DRUG

Intravenous infusion of LP-184 on Day 1 and Day 8 of a 21-day cycle.

LP-184 is an investigational semisynthetic acylfulvene administered intravenously on days 1 and 8 of each 21-day cycle. In Phase Ib, the starting dose is 0.39 mg/kg, with predefined dose de-escalation levels of 0.31 mg/kg and 0.25 mg/kg. In Phase II, LP-184 will be administered at the recommended Phase II dose (RP2D) established during Phase Ib. Treatment may continue for up to one year or until disease progression, unacceptable toxicity, or other protocol-defined discontinuation criteria.

Locations (1)

Rigshospitalet, Phase 1 Unit, Department of Oncology, Section 5073. Address: Blegdamsvej 9, 2100 Copenhagen, Denmark

Copenhagen, Denmark